ELAC2 is a functional prostate cancer risk allele.


Journal

Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 30 05 2023
accepted: 06 06 2023
pmc-release: 01 08 2024
medline: 17 7 2023
pubmed: 24 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

Stentenbach and colleagues have unveiled a functional role of a human germline mutation found in the ribonuclease (RNase) Z enzyme, ELAC2, in prostate cancer. Here, we discuss the importance of these findings in enhancing our understanding of how risk variants enable prostate cancer progression and the post-transcriptional mechanisms underlying oncogenesis.

Identifiants

pubmed: 37353407
pii: S1471-4914(23)00121-1
doi: 10.1016/j.molmed.2023.06.002
pmc: PMC10527048
mid: NIHMS1907104
pii:
doi:

Substances chimiques

ELAC2 protein, human 0
Neoplasm Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-588

Subventions

Organisme : NCI NIH HHS
ID : R01 CA276308
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM135362
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA230617
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009515
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests No interests are declared.

Références

Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366581
Nat Cancer. 2022 Dec;3(12):1484-1497
pubmed: 36510010
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
Elife. 2022 Sep 15;11:
pubmed: 36107759
Nat Genet. 2021 Jan;53(1):65-75
pubmed: 33398198
EMBO Mol Med. 2023 Jun 7;15(6):e17463
pubmed: 37093546
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Eur Urol. 2021 Aug;80(2):134-138
pubmed: 33941403
Cell. 2016 Jun 2;165(6):1416-1427
pubmed: 27259150
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14134-9
pubmed: 20679199

Auteurs

Steven Blinka (S)

Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; School of Medicine, University of Washington, Seattle, WA 98195, USA.

Rashmi Mishra (R)

Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Andrew C Hsieh (AC)

Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; School of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: ahsieh@fredhutch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH